福岡県北九州市の岩本内科医院は、世界的評価を受ける肝臓癌の手術・治療(門脈・動脈・同時塞療法)と、地域医療の実践を行っています。

治療実績performance

  • 当院ブログで、実施した治療・手術内容について詳しく紹介しております。

理事長経歴/研究実績

理事長写真

業績リスト


2005年3月
久留米大学医学部卒業 医師国家資格取得

2005年4月
久留米大学病院初期臨床研修 開始

2007年3月
久留米大学病院初期臨床研修 修了

2007年4月
久留米大学医学部内科学講座消化器内科部門 入局 専修医

2008年4月
久留米大学大学院 入学

2011年3月
久留米大学大学院 卒業 医学博士取得
(学位論文)Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. Neoplasia 2011 Mar;13(3):187-97
2012年度 久留米大学学術奨励賞 獲得

2011年4月
久留米大学内科学講座消化器内科部門 助教
2012年度 CANGO研究助成金 獲得
2012年度 九大海外助成金 獲得

2012年1月
スウェーデン カロリンスカ研究所 Yihai Cao研究室(Department of Microbiology, Tumor and Cell biology)客員研究員

2014年4月
同研究室 正規ポスドク研究員
2014年度 カロリンスカポスドク研究奨励金 獲得

2014年5月
医療法人 岩本内科医院理事長 就任

2015年2月
久留米大学内科学講座消化器内科部門 助教
2015年度 科学研究費若手研究B 獲得
2015年度 石橋学術研究奨励金 獲得
2016年度 新日本先進医療研究財団 研究助成金 獲得
2017年度 アメリカ肝臓学会年次総会(AASLD)優秀演題賞
2017年度 武田科学振興財団 医学系研究助成
2018年度 科学研究費若手研究 獲得

覚悟の瞬間に取材されました。掲載記事ははこちらよりご覧ください。

研究業績

研究業績一覧より、理事長の研究実績をご確認いただけます。

研究業績一覧
Effects of In-Hospital Exercise on Sarcopenia in Hepatoma Patients Who Underwent Transcatheter Arterial Chemoembolization.
Koya S, Kawaguchi T, Hashida R, Hirota K, Bekki M, Goto E, Yamada M, Sugimoto M, Hayashi S, Goshima N, Yoshiyama T, Otsuka T, Nozoe R, Nagamatsu A, Nakano D, Shirono T, Shimose S, Iwamoto H, Niizeki T, Matsuse H, Koga H, Miura H, Shiba N, Torimura T. J Gastroenterol Hepatol. 2018 Nov 7. doi: 10.1111/jgh.14538. [Epub ahead of print]
Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
Shirono T, Iwamoto H, Niizeki T, Shimose S, Nakano M, Satani M, Okamura S, Noda Y, Kamachi N, Kuromatsu R, Sakai M, Nomiyama M, Kuwano T, Tanaka M, Koga H, Torimura T. Oncology. 2018 Oct 5:1-8. doi: 10.1159/000492822. [Epub ahead of print]
High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine.
Wada F, Koga H, Akiba J, Niizeki T, Iwamoto H, Ikezono Y, Nakamura T, Abe M, Masuda A, Sakaue T, Tanaka T, Kakuma T, Yano H, Torimura T. Cancer Sci. 2018 Sep;109(9):2801-2810. doi: 10.1111/cas.13728. Epub 2018 Aug 16.
Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance.
Iwamoto H, Abe M, Yang Y, Cui D, Seki T, Nakamura M, Hosaka K, Lim S, Wu J, He X, Sun X, Lu Y, Zhou Q, Shi W, Torimura T, Nie G, Li Q, Cao Y. Cell Metab. 2018 Jul 3;28(1):104-117.e5. doi: 10.1016/j.cmet.2018.05.005.
Epub 2018 May 31.
Ablation of endothelial VEGFR1 improves metabolic dysfunction by inducing adipose tissue browning.
Seki T, Hosaka K, Fischer C, Lim S, Andersson P, Abe M, Iwamoto H, Gao Y, Wang X, Fong GH, Cao Y. J Exp Med. 2018 Feb 5;215(2):611-626. doi: 10.1084/jem.20171012. Epub 2018 Jan 5.
Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study.
Nakano M, Niizeki T, Nagamatsu H, Tanaka M, Kuromatsu R, Satani M, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Mol Clin Oncol. 2017 Dec;7(6):1013-1020. doi: 10.3892/mco.2017.1442. Epub 2017 Oct 4.
Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production.
Nakamura M, Zhang Y, Yang Y, Sonmez C, Zheng W, Huang G, Seki T, Iwamoto H, Ding B, Yin L, Foukakis T, Hatschek T, Li X, Hosaka K, Li J, Yu G, Wang X, Liu Y, Cao Y. Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):E9635-E9644. doi: 10.1073/ pnas.1703431114. Epub 2017 Oct 23.
Pigment Epithelium-Derived Factor (PEDF) Prevents Hepatic Fat Storage, Inflammation, and Fibrosis in Dietary Steatohepatitis of Mice.
Yoshida T, Akiba J, Matsui T, Nakamura K, Hisamoto T, Abe M, Ikezono Y, Wada F, Iwamoto H, Nakamura T, Koga H, Yamagishi SI, Torimura T. Dig Dis Sci. 2017 Jun;62(6):1527-1536. doi: 10.1007/s10620-017-4550-x.
Epub 2017 Apr 1.
Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
Ikezono Y, Koga H, Akiba J, Abe M, Yoshida T, Wada F, Nakamura T, Iwamoto H, Masuda A, Sakaue T, Yano H, Tsuruta O, Torimura T. Mol Cancer Res. 2017 Jun;15(6):744-752. doi: 10.1158/1541-7786.MCR-16- 0285. Epub 2017 Feb 8.
Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism.
Yang Y, Zhang Y, Iwamoto H, Hosaka K, Seki T, Andersson P, Lim S, Fischer C, Nakamura M, Abe M, Cao R, Skov PV, Chen F, Chen X, Lu Y, Nie G, Cao Y. Nat Commun. 2016 Sep 1;7:12680. doi: 10.1038/ncomms12680.
Endothelial PDGF-CC regulates angiogenesis-dependent thermogenesis in beige fat.
Seki T, Hosaka K, Lim S, Fischer C, Honek J, Yang Y, Andersson P, Nakamura M, Näslund E, Ylä-Herttuala S, Sun M, Iwamoto H, Li X, Liu Y, Samani NJ, Cao Y. Nat Commun. 2016 Aug 5;7:12152. doi: 10.1038/ncomms12152.
Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Satani M, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group Of Japan. Oncotarget. 2016 Sep 27;7(39):64400-64409. doi: 10.18632/oncotarget.
10794
Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
Torimura T, Iwamoto H, Nakamura T, Abe M, Ikezono Y, Wada F, Sakaue T, Masuda H, Hashimoto O, Koga H, Ueno T, Yano H. Neoplasia. 2016 Jul;18(7):413-24. doi: 10.1016/j.neo.2016.05.001.
Diffusion-weighted magnetic resonance imaging predicts malignant potential in small hepatocellular carcinoma.
Okamura S, Sumie S, Tonan T, Nakano M, Satani M, Shimose S, Shirono T, Iwamoto H, Aino H, Niizeki T, Tajiri N, Kuromatsu R, Okuda K, Nakashima O, Torimura T. Dig Liver Dis. 2016 Aug;48(8):945-52. doi: 10.1016/j.dld.2016.05.020.
Epub 2016 Jun 1.
Ex vivo expansion of circulating CD34(+) cells enhances the regenerative effect on rat liver cirrhosis.
Nakamura T, Koga H, Iwamoto H, Tsutsumi V, Imamura Y, Naitou M, Masuda A, Ikezono Y, Abe M, Wada F, Sakaue T, Ueno T, Ii M, Alev C, Kawamoto A, Asahara T, Torimura T. Mol Ther Methods Clin Dev. 2016 Apr 27;3:16025. doi: 10.1038/mtm.2016.25. eCollection 2016.
The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages.
Yang Y, Andersson P, Hosaka K, Zhang Y, Cao R, Iwamoto H, Yang X, Nakamura M, Wang J, Zhuang R, Morikawa H, Xue Y, Braun H, Beyaert R, Samani N, Nakae S, Hams E, Dissing S, Fallon PG, Langer R, Cao Y. Nat Commun. 2016 May 6;7:11385. doi: 10.1038/ncomms11385.
Effects of in-hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease.
Koya S, Kawaguchi T, Hashida R, Goto E, Matsuse H, Saito H, Hirota K, Taira R, Matsushita Y, Imanaga M, Nagamatsu A, Shirono T, Shimose S, Iwamoto H, Niizeki T, Kuromatsu R, Miura H, Shiba N, Torimura T. Hepatol Res. 2017 Mar;47(3):E22-E34. doi: 10.1111/hepr.12718. Epub 2016 May 5.
Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study.
Nagamatsu H, Sumie S, Niizeki T, Tajiri N, Iwamoto H, Aino H, Nakano M, Shimose S, Satani M, Okamura S, Kuromatsu R, Matsugaki S, Kurogi J, Kajiwara M, Koga H, Torimura T. Cancer Chemother Pharmacol. 2016 Feb;77(2):243-50. doi: 10.1007/s00280- 015-2892-7. Epub 2016 Jan 11.
High expression of the putative cancer stem cell marker, DCLK1, in rectal neuroendocrine tumors.
Ikezono YU, Koga H, Abe M, Akiba J, Kawahara A, Yoshida T, Nakamura T, Iwamoto H, Yano H, Kage M, Sata M, Tsuruta O, Torimura T. Oncol Lett. 2015 Oct;10(4):2015-2020. Epub 2015 Jul 20.
PlGF-induced VEGFR1-dependent vascular remodeling determines opposing antitumor effects and drug resistance to Dll4-Notch inhibitors.
Iwamoto H, Zhang Y, Seki T, Yang Y, Nakamura M, Wang J, Yang X, Torimura T, Cao Y. Sci Adv. 2015 Apr 10;1(3):e1400244. doi: 10.1126/sciadv.1400244.
eCollection 2015 Apr.
Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Tajiri N, Satani M, Niizeki T, Aino H, Okamura S, Iwamoto H, Shimose S, Shirono T, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Cancer Med. 2015 Dec;4(12):1836-43. doi: 10.1002/cam4.548. Epub 2015 Oct 16.
VEGF-B promotes cancer metastasis through a VEGF-A-independent mechanism and serves as a marker of poor prognosis for cancer patients.
Yang X, Zhang Y, Hosaka K, Andersson P, Wang J, Tholander F, Cao Z, Morikawa H, Tegnér J, Yang Y, Iwamoto H, Lim S, Cao Y.
Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):E2900-9. doi: 10.1073/pnas. 1503500112. Epub 2015 May 19.
Inhibition of hypoxia-inducible factor via upregulation of von Hippel- Lindau protein induces "angiogenic switch off" in a hepatoma mouse model.
Iwamoto H, Nakamura T, Koga H, Izaguirre-Carbonell J, Kamisuki S, Sugawara F, Abe M, Iwabata K, Ikezono Y, Sakaue T, Masuda A, Yano H, Ohta K, Nakano M, Shimose S, Shirono T, Torimura T. Mol Ther Oncolytics. 2015 Dec 2;2:15020. doi: 10.1038/mto.2015.20. eCollection 2015.
Brown adipose tissue, thermogenesis, angiogenesis: pathophysiological aspects.
Honek J, Lim S, Fischer C, Iwamoto H, Seki T, Cao Y. Horm Mol Biol Clin Investig. 2014 Jul;19(1):5-11. doi: 10.1515/hmbci- 2014-0014. Review.
Modulation of age-related insulin sensitivity by VEGF-dependent vascular plasticity in adipose tissues.
Honek J, Seki T, Iwamoto H, Fischer C, Li J, Lim S, Samani NJ, Zang J, Cao Y. Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14906-11. doi: 10.1073/ pnas.1415825111. Epub 2014 Sep 30.
TNFR1 mediates TNF-α-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling.
Ji H, Cao R, Yang Y, Zhang Y, Iwamoto H, Lim S, Nakamura M, Andersson P, Wang J, Sun Y, Dissing S, He X, Yang X, Cao Y. Nat Commun. 2014 Sep 17;5:4944. doi: 10.1038/ncomms5944.
CD34(+) cell therapy is safe and effective in slowing the decline of hepatic reserve function in patients with decompensated liver cirrhosis.
Nakamura T, Torimura T, Iwamoto H, Kurogi J, Inoue H, Hori Y, Sumie S, Fukushima N, Sakata M, Koga H, Abe M, Ikezono Y, Hashimoto O, Ueno T, Oho K, Okamura T, Okuda S, Kawamoto A, Ii M, Asahara T, Sata M. J Gastroenterol Hepatol. 2014 Oct;29(10):1830-8. doi: 10.1111/jgh.12622.
Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma.
Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, Kerbel RS, Sata M. Transl Oncol. 2013 Oct 1;6(5):511-9. eCollection 2013. Review.
Methylated-(3'')-epigallocatechin gallate analog suppresses tumor growth in Huh7 hepatoma cells via inhibition of angiogenesis.
Hashimoto O, Nakamura A, Nakamura T, Iwamoto H, Hiroshi M, Inoue K, Torimura T, Ueno T, Sata M. Nutr Cancer. 2014;66(4):728-35. doi: 10.1080/01635581.2013.783601. Epub 2013 Sep 13.
Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.
Yang Y, Zhang Y, Cao Z, Ji H, Yang X, Iwamoto H, Wahlberg E, Länne T, Sun B, Cao Y. Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12018-23. doi: 10.1073/
pnas.1301331110. Epub 2013 Jul 1.
Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Sakata K, Matsugaki S, Kajiwara M, Fukuizumi K, Tajiri N, Matsukuma N, Sakai T, Ono N, Yano Y, Koga H, Kurogi J, Takata A, Sumie S, Satani M, Yamada S, Niizeki T, Aino H, Iwamoto H, Torimura T, Sata M. Oncology. 2013;84(2):108-14. doi: 10.1159/000342650. Epub 2012 Nov 9.
Adiponectin suppresses endoplasmic reticulum stress in nonalcoholic steatohepatitis.
Ueno T, Nakamura A, Nakayama H, Otabe S, Yuan X, Fukutani T, Iwamoto H, Nakamura T, Koga H, Torimura T, Sata M, Yamada K. Exp Ther Med. 2011 Nov;2(6):1035-1040. Epub 2011 Sep 2.
Transplantation of endothelial progenitor cells ameliorates vascular dysfunction and portal hypertension in carbon tetrachloride-induced rat liver cirrhotic model.
Sakamoto M, Nakamura T, Torimura T, Iwamoto H, Masuda H, Koga H, Abe M, Hashimoto O, Ueno T, Sata M. J Gastroenterol Hepatol. 2013 Jan;28(1):168-78. doi: 10.1111/j.1440-1746. 2012.07238.x.
Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice.
Inoue K, Torimura T, Nakamura T, Iwamoto H, Masuda H, Abe M, Hashimoto O, Koga H, Ueno T, Yano H, Sata M. Clin Cancer Res. 2012 Jul 15;18(14):3924-33. doi: 10.1158/1078-0432.CCR- 11-2041. Epub 2012 May 18.
Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy.
Niizeki T, Sumie S, Torimura T, Kurogi J, Kuromatsu R, Iwamoto H, Aino H, Nakano M, Kawaguchi A, Kakuma T, Sata M. J Gastroenterol. 2012 Jun;47(6):686-95. doi: 10.1007/s00535-012-0555-6.
Epub 2012 Mar 1.
Prevention of liver fibrosis and liver reconstitution of DMN-treated rat liver by transplanted EPCs.
Nakamura T, Torimura T, Iwamoto H, Masuda H, Naitou M, Koga H, Abe M, Hashimoto O, Tsutsumi V, Ueno T, Sata M. Eur J Clin Invest. 2012 Jul;42(7):717-28. doi: 10.1111/j.1365-2362.2011. 02637.x. Epub 2012 Jan 7.
Hepatitis C virus core protein upregulates the expression of vascular endothelial growth factor via the nuclear factor-κB/hypoxia-inducible factor-1α axis under hypoxic conditions.
Abe M, Koga H, Yoshida T, Masuda H, Iwamoto H, Sakata M, Hanada S, Nakamura T, Taniguchi E, Kawaguchi T, Yano H, Torimura T, Ueno T, Sata M. Hepatol Res. 2012 Jun;42(6):591-600. doi: 10.1111/j.1872-034X.2011.00953.
x. Epub 2012 Jan 6.
Interaction of endothelial progenitor cells expressing cytosine deaminase in tumor tissues and 5-fluorocytosine administration suppresses growth of 5-fluorouracil-sensitive liver cancer in mice.
Torimura T, Ueno T, Taniguchi E, Masuda H, Iwamoto H, Nakamura T, Inoue K, Hashimoto O, Abe M, Koga H, Barresi V, Nakashima E, Yano H, Sata M. Cancer Sci. 2012 Mar;103(3):542-8. doi: 10.1111/j.1349-7006.2011.02182.x.
Epub 2012 Jan 25.
Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.
Iwamoto H, Torimura T, Nakamura T, Hashimoto O, Inoue K, Kurogi J, Niizeki T, Kuwahara R, Abe M, Koga H, Yano H, Kerbel RS, Ueno T, Sata M. Neoplasia. 2011 Mar;13(3):187-97.
Recent progress in the management of hepatocellular carcinoma detected during a surveillance program in Japan.
Nakano M, Ando E, Kuromatsu R, Torimura T, Sumie S, Takata A, Fukushima N, Kurogi J, Niizeki T, Iwamoto H, Tanaka M, Sata M. Hepatol Res. 2010 Oct;40(10):989-96. doi: 10.1111/j.1872-034X.2010.00706.x.
HCC develops even in the early stage of chronic liver disease in elderly patients with HCV infection.
Takata A, Kuromatsu R, Ando E, Iwamoto H, Fukushima N, Sumie S, Torimura T, Sata M. Int J Mol Med. 2010 Aug;26(2):249-56.
Excellent outcomes with angiographic subsegmentectomy in the treatment of typical hepatocellular carcinoma: a retrospective study of local recurrence and long-term survival rates in 120 patients with hepatocellular carcinoma.
Iwamoto S, Yamaguchi T, Hongo O, Iwamoto H, Sanefuji H. Cancer. 2010 Jan 15;116(2):393-9. doi: 10.1002/cncr.24678.

当院の治療実績一覧

年間血管造影治療件数

治療件数
2018 552
2017 502
2016 373
2015 217
2014 171
2013 172
2012 185
2011 116

県外来院がん患者数(過去5年間)

都道府県 患者数
大阪 29
広島 15
愛知 14
東京 13
山口 12
その他 107

肝臓がんに対する門脈動脈同時塞栓療法の治療成績

肝癌ステージ 5年生存率 10年生存率
1 73.9% 40.4%
2 59.6% 17.3%
3 43.6%
4 33.0%
HOME > 治療実績